Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rasmus Jansson-Löfmark

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Nucleic Acid Therapeutics|October 18, 2018
Inferring Half-Lives at the Effect Site of Oligonucleotide DrugsRasmus Jansson-Löfmark, Peter Gennemark
Clinical Pharmacology and Therapeutics|April 11, 2020
Does In Vitro Potency Predict Clinically Efficacious Concentrations?Rasmus Jansson-Löfmark, Stephan Hjorth, Johan Gabrielsson
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
ADME: Assessing Pharmacokinetic-Pharmacodynamic Parameters of OligonucleotidesRasmus Jansson-Löfmark, Christine Ahlström, Peter Gennemark
Clinical Pharmacokinetics|February 9, 2026
Systemic Pharmacokinetic Principles of Therapeutic PeptidesPär Nordell, Rasmus Jansson-Löfmark, Peter Gennemark
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 13, 2021
Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR)Lambertus A Peletier, Rasmus Jansson-Löfmark, Johan Gabrielsson
Journal of Pharmacokinetics and Pharmacodynamics|November 4, 2010
Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusionsChristine Ahlström, Lambertus A Peletier, Rasmus Jansson-Löfmark, et al.
The AAPS Journal|September 4, 2025
Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African TrypanosomiasisMikael Boberg, Kesara Na-Bangchang, Michael Ashton, et al.
Drug Discovery Today|June 1, 2018
Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug developmentShalini Andersson, Madeleine Antonsson, Marie Elebring, et al.
Drug Discovery Today|December 12, 2018
Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745Shalini Andersson, Madeleine Antonsson, Marie Elebring, et al.
ACS Omega|September 28, 2020
Chiral Chromatographic Isolation on Milligram Scale of the Human African Trypanosomiasis Treatment d- and l-EflornithineMikael Boberg, Anna C Jonson, Hanna Leek, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Nucleic Acid Therapeutics|October 18, 2018
Inferring Half-Lives at the Effect Site of Oligonucleotide DrugsRasmus Jansson-Löfmark, Peter Gennemark
Clinical Pharmacology and Therapeutics|April 11, 2020
Does In Vitro Potency Predict Clinically Efficacious Concentrations?Rasmus Jansson-Löfmark, Stephan Hjorth, Johan Gabrielsson
Methods in Molecular Biology (Clifton, N.J.)|August 15, 2019
ADME: Assessing Pharmacokinetic-Pharmacodynamic Parameters of OligonucleotidesRasmus Jansson-Löfmark, Christine Ahlström, Peter Gennemark
Clinical Pharmacokinetics|February 9, 2026
Systemic Pharmacokinetic Principles of Therapeutic PeptidesPär Nordell, Rasmus Jansson-Löfmark, Peter Gennemark
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 13, 2021
Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR)Lambertus A Peletier, Rasmus Jansson-Löfmark, Johan Gabrielsson
Journal of Pharmacokinetics and Pharmacodynamics|November 4, 2010
Feedback modeling of non-esterified fatty acids in rats after nicotinic acid infusionsChristine Ahlström, Lambertus A Peletier, Rasmus Jansson-Löfmark, et al.
The AAPS Journal|September 4, 2025
Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African TrypanosomiasisMikael Boberg, Kesara Na-Bangchang, Michael Ashton, et al.
Drug Discovery Today|June 1, 2018
Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug developmentShalini Andersson, Madeleine Antonsson, Marie Elebring, et al.
Drug Discovery Today|December 12, 2018
Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745Shalini Andersson, Madeleine Antonsson, Marie Elebring, et al.
ACS Omega|September 28, 2020
Chiral Chromatographic Isolation on Milligram Scale of the Human African Trypanosomiasis Treatment d- and l-EflornithineMikael Boberg, Anna C Jonson, Hanna Leek, et al.
Pageof 5